Stroke Prevention, Thrombolytic Therapy, and Rehab

5.5 Contact Hours


By the completion of this activity, the learner will be able to:

  1. Recall vital statistics regarding stroke in the US and worldwide and the basics of cerebral vascular anatomy.
  2. Review the pathophysiology involved in both ischemic and hemorrhagic strokes
  3. List the risk factors for stroke as well as methods for prevention
  4. Explain the signs and symptoms of a stroke
  5. Identify the components of a full stroke work-up and acute treatment options, including surgical treatment for hemorrhagic strokes, the use of thrombolytics as well as endovascular procedures as well
  6. Discuss the rehabilitation that should occur following a stroke



            Globally, cardiovascular disease is the number one cause of death. In 2016, 31% of all global deaths, or an estimated 17.9 million people, died from cardiovascular diseases.  85% of these are due to heart attack or stroke. Over 75% of these deaths occur in middle-to-low income countries (World Health Organization, 2017). Just within the United States adult population, roughly 7.2 million people self-report having had a stroke. Each year around 800,000 people in the US have a stroke, or around one person every 40 seconds nationwide. It is more common in black Americans and Native Americans/Alaskan Natives than white Americans, and more women die secondary to stroke than men. Stroke is the fifth leading cause of death in the United States (Benjamin et al, 2018). In the US, more than 140,000 people die annually following a stroke, or about 1 in every 20 adult deaths. The good news is that the stroke death rate has declined since at least the 1960’s, down an impressive 35.8% in the US from 2000 to 2010. This is largely related to an improved ability to treat the conditions that increase stroke risk as well as technology to treat patients diagnosed with stroke. The bad news is that the rate of decline in the stroke death rate has slowed since 2000, and even increased slightly since 2013, especially among black males. The estimated cost of stroke in the US is $34 billion annually, including the cost of healthcare services, medications, and lost productivity. There is a significant variation in mortality regionally across the US, with a much higher death rate seen in the “stroke belt” of the southeast (North and South Carolina, Georgia, Tennessee, Mississippi, Alabama, Louisiana and Arkansas) (Winstein et al., 2016; Bowen, 2016; Centers for Disease Control and Prevention [CDC], 2018). See the below map for mortality rates from stroke nationwide:


    The anatomy of cerebral circulation starts with the common carotid arteries, which split into the external and internal carotid arteries. The external carotid arteries supply the posterior scalp and face. The internal carotid arteries (ICA) supply blood to roughly 80% of the cerebrum. From this, the anterior cerebral artery branches off to supply the superior portion of the frontal and parietal lobes. The ophthalmic artery and middle cerebral artery (MCA) also branch off of the ICA. The ophthalmic artery supplies the ocular orbit as well as some structures in the nose, face and meninges. The MCA supplies the remainder of the lateral cortex, such as most of the frontal and parietal lobes, as well as the superior and medial portions of the temporal lobe, the basal ganglia and the internal capsule. Posterior circulation starts with the vertebral arteries, which branch off of the subclavian arteries and travel up through the transverse foramina of the cervical vertebra and through the foramen magnum to supply blood to the cranial bones and meninges, and converge to form the basilar artery. The basilar artery supplies blood to the pons, cerebellum, and inner ear. The basilar artery splits into the posterior communicating artery to form the Circle of Willis, which surrounds the pituitary gland, although only about 20% of the population has a complete arterial circle. The posterior cerebral artery then branches off to supply the inferior and medial portions of the temporal and occipital lobes, the midbrain, and the thalamus (Franco, 2018).

(Image courtesy of: University of Miami Miller School of Medicine)

There are two different general types of stroke- an ischemic stroke in which blood flow to an area is reduced to critical levels or stopped completely, and a hemorrhagic stroke in which there is abnormal bleeding into an area. Ischemic strokes can either be caused by a thrombus, which is a blood clot which forms in an artery that supplies blood to the brain, or embolus, which is a blood clot, plaque, or fatty tissue that travels from somewhere else in the body (such as the heart or the peripheral vasculature) and becomes lodged in and blocks an artery that supplies the brain. In both types of ischemic stroke, the plaque or clot keeps oxygen-rich blood from getting to a portion of the brain, and neurons which are deprived of oxygen start to die within minutes. This is most commonly caused by atherosclerosis, which is a condition in which a fatty substance called plaque builds up along the walls of arteries. This plaque formation hardens and narrows arteries, and the plaque can crack or rupture, attracting platelets and eventually leading to the formation of blood clots. If a plaque formation breaks off into the artery, this can then create an embolus downstream. Atrial fibrillation (Afib) is an irregular rhythm that allows for pooling of blood in the atrium of the heart, which increases the risk of embolic stroke if a blood clot forms there and is then expelled and travels up to the brain.

(Image courtesy of NHLBI)

A hemorrhagic stroke can either be caused by bleeding into the parenchyma of the brain (intracerebral hemorrhage [ICH]) or in the space around the brain between the inner and middle membranes (subarachnoid hemorrhage [SAH]). In both types of hemorrhagic stroke, the blood causes swelling and cellular damage in the surrounding brain tissue as well as increased pressure within the skull, which is a closed container. SAHs are often caused by a ruptured aneurysm, which is a weakened bulge in an artery, and ICHs may be caused by hypertension, trauma, or an arteriovenous malformation (AVM), which is an abnormal clustered connection of blood vessels between arteries and veins. (National Heart, Lung, and Blood Institute [NHLBI], n.d.). Hemorrhagic strokes may also be caused by medications, coagulopathy, sympathomimetic drugs of abuse, and cerebral amyloid angiopathy. Ischemic strokes account for 87%, while ICHs account for 10% and SAHs account for 3% of all strokes (Benajmin et al., 2018 and Franco, 2018).

(Image courtesy of NHLBI)

Risk Factors and Prevention

    Risk factors for a stroke include non-modifiable and modifiable factors. Non-modifiable factors include age, sex, and race. Stroke is more common with advanced age. In younger age groups, stroke is more common in men, but the mortality rate from stroke is higher in women. Perhaps add why women die more also after menopause the risk increases for women.Stroke is more common among certain racial groups, especially black men and people of Native American or Alaska Native decent. Family history of stroke and the presence of brain aneurysms or AVMs are other risk factors that cannot be modified. Modifiable risk factors for stroke includes hypertension, high cholesterol, diabetes, heart disease (such as coronary artery disease [CAD], cardiomyopathy, heart failure, and Afib), smoking, alcohol and drug use (more than one alcoholic drink per day, cocaine use and IV drug use), sickle cell disease, vasculitis, lack of physical activity, being overweight/obesity, stress, depression, unhealthy diet, and the use of certain medications, such as hormonal birth control and nonsteroidal anti-inflammatory drugs. Smoking damages and tightens blood vessels, raising the risk of stroke (NHLBI, n.d.). Of the modifiable risk factors listed above, the American Heart Association( AHA) (Benajmin et al., 2018) reports that adequate hypertension treatment is the most important to decrease the overall risk of stroke. A diagnosis of atrial fibrillation increases a person’s risk of stroke as much as 5x (Wandell et al., 2017). There is also an increased risk of stroke for people who regularly experience extreme climates and those with lower income. A regional increased risk of stroke can also be seen, as mentioned above, in areas like the southeastern United States “stroke belt”. The theory is that the diet, lifestyle, and racial profiles seen in this area of the country are the reasoning behind this trend. Some medical conditions can increase the risk of stroke, such as fibromuscular dysplasia, septal defects such as patent foramen ovale (PFO), and an increased red blood cell count. In children, congenital heart defects, immune disorders, arterial disorders, blood clotting disorders, head and neck trauma, and a maternal history of infertility, infection of the amniotic fluid, premature rupture of membranes and maternal hypertension all increase the risk for stroke (Franco, 2018).

    Given the large number of modifiable risk factors, medical providers have focused on prevention as the first step in treating stroke. Primary prevention, which means preventing a first stroke, is primarily focused on treating and controlling risk factors. This means actively and appropriately managing hypertension, as well as diabetes, Afib, and any other risk factors. Following a heart-healthy lifestyle, which includes regular exercise, and a healthy diet (a diet high in fiber, fruits, vegetables, whole grains and lean meat and low in saturated fats, trans fats, sodium, added sugar and alcohol) can help to lower the risk of stroke. This also includes a weight loss  program to maintain a healthy body weight. Quitting smoking also decreases the risk of stroke, along with numerous other detrimental effects of smoking. Managing stress can also decrease the risk of stroke (Franco, 2018; NHLBI, n.d.). The AHA (2017) ,recently published a guideline on the importance of self care for stroke and other cardiovascular disease prevention. Self-care is defined as a process “whereby individuals and families maintain health through health-promoting practices and managing illness”. They break this down into three general categories: self-care maintenance which includes maintaining physical and emotional stability, self-care monitoring which includes observing oneself for changes in signs or symptoms (also called “body listening”), and self-care management which includes appropriately responding to signs or symptoms if and when they occur. Other than the previously mentioned individual level prevention techniques discussed, they also refer to the importance of positive family support as well as community-level prevention methods such as access to medical services, healthy food, open spaces, a safe environment, healthy air, regular physical activity, and social cohesion (Riegel et al., 2017). 

One in four stroke survivors has another stroke within 5 years, and the risk of a stroke within 90 days of a transient ischemic attack (TIA) is as high as 17% (CDC, 2018). Secondary prevention refers to those things aimed at preventing a recurrent stroke after an initial stroke or TIA. The American Stroke Association (ASA) and AHA (2018) publishes early management guidelines for acute ischemic stroke patients. Regarding hypertensive stroke patients, after the initial 72 hours, it is safe and reasonable to initiate or restart antihypertensive medications before discharge if blood pressure is consistently above 140/90. They recommend that patients should be started on (at 24-72 hours post-stroke) and discharged home on antiplatelet medication following an initial stroke if that stroke was not felt to be cardioembolic, and recommend dual antiplatelet therapy (with aspirin and clopidogrel [Plavix]) for 21 days, followed by clopidogrel alone for a total of 90 days. Patients with cardioembolic strokes related to a history of Afib should be started on anticoagulation medication within 4-14 days of an initial stroke if not already on one to prevent another stroke. In a patient with concurrent coronary artery disease, the use of dual antiplatelet and anticoagulation therapy is uncertain according to the ASA (Powers et al., 2018). However, studies have found that the use of anticoagulation medication(s), even combinations of two medications, in patients with Afib does not increase the risk of hemorrhagic stroke as one might otherwise expect. The risk of death does however increase in these patients if a hemorrhagic stroke does occur (Wandell et al, 2017). In patients diagnosed with a stroke secondary to a vertebral or carotid artery dissection, secondary prevention with antiplatelet or anticoagulation medication for 3-6 months following the stroke is reasonable. Checking cholesterol levels or routine echocardiograms are not recommended for secondary prevention on a routine basis after a stroke that is presumed athersclerotic in origin unless it is with the sole purpose of assessing the effectiveness of a previously prescribed statin medication. Continuation of a statin medication in the acute phase following a stroke is reasonable, and high intensity statin therapy is recommended in patients 75 and under following an acute stroke. Moderate intensity therapy should be considered for patients over the age of 75. Lifestyle and diet modification should be attempted in these patients as well. If a patient is suspected or known to have had a stroke in the carotid territory and may be a candidate for stent placement of carotid endarterectomy (CEA), noninvasive imaging of the cervical vessels should be done within 24 hours of admission, but the potential benefit of urgent or emergent CEA procedures in the acute phase following a stroke is not well established. Routine screening for obstructive sleep apnea (OSA) or antiphospholipid antibodies following a stroke is not recommended. Finally, secondary prevention measures after a stroke should include managing or treating any medical conditions discussed above as a primary prevention measure, such as quitting smoking and a heart-healthy lifestyle (Powers et al., 2018). Many of the secondary prevention measures discussed here are also core/primary stroke clinical performance measures (CPMs) published by the Joint Commission (JCAHO), including the use of antiplatelet medication, anticoagulants, and lipid-lowering statin medications for secondary prevention post-stroke (JCAHO, 2018b). A specific secondary prevention measure that has been tested with some favorable results in stroke patients is repetitive bilateral arm ischemic preconditioning (BAIPC). This method aims to improve cerebral perfusion and thus decrease the risk of stroke recurrence. In a study published by Meng et al. (2015), a group of 58 patients over the age of 80 were enrolled in the study which randomized them into a test or control group. The test group was instructed to perform five cycles twice daily of bilateral arm ischemia lasting five minutes per cycle for 180 days starting about 7 days following either a stroke or TIA while the control group was given a sham exercise to perform. The test group (n=30) had a total of 2 recurrent infarcts and 7 TIAs during the study period while the control group (n=28) had 8 infarcts and 11 TIAs during the same period of time. The test group also showed decreased levels of c-reactive protein (CRP), interleukin-6, leukocyte counts and a decreased platelet aggregation rate and increased plasma tissue plasminogen activator compared to the control group participants (Meng et al., 2015).

Stroke Signs and Symptoms

Signs and symptoms of a stroke can develop very quickly, over minutes, or more slowly, over hours or days. They will vary depending on the area of the brain that has been effected.  These symptoms will last for at least 24 hours. Symptoms of a stroke that resolve spontaneously in less than 24 hours, and usually in 1-2 hours, are called transient ischemic attacks (TIAs). Common signs and symptoms of a stroke include:

  • Weakness, usually on one side of the body
  • Paralysis or numbness of the face, arms, or legs, usually on one side of the body
  • Confusion
  • Difficulty speaking or understanding speech
  • Vision changes in one or both eye(s)
  • Difficulty breathing
  • Dizziness
  • Difficulty walking or unexplained fall(s)
  • Loss of balance and/or coordination
  • Loss of consciousness
  • Sudden and severe headache (usually indicates a hemorrhagic stroke)

The importance of public education campaigns such as FAST (Face, Arms, Speech, Time to call 911) that target stroke education can not be overstated (see figure below). The general public has a long-held false belief that strokes are not medical emergencies worthy of initiating the emergency management system (EMS). Patients should all be made aware that when signs or symptoms of a stroke are seen, the only acceptable response is to call 911 for an ambulance transport to a hospital equipped to manage acute strokes (CDC, 2018; NHLBI, n.d.). Aphasia is a common stroke symptom that is defined as difficulty understanding speech, speaking, reading, or writing language. It affects up to one third of all stroke patients and is usually seen in strokes affecting the left side of the brain. Unfortunately, 30-40% of those diagnosed with aphasia symptoms immediately following a stroke develop chronic difficulty (Palmer, 2015). A brainstem stroke, which account for 10% of all ischemic strokes, that affects the pons is also called a pontine stroke. If severe enough, these can cause “locked-in syndrome”, which is a complete lack of control of motor function with the exception of the eyes, but maintained cognitive function (Franco, 2018).

(Image courtesy of CDC, 2018)

Acute Evaluation

            As stated above, acute evaluation and treatment for stroke symptoms should start with EMs providers. The ASA (2018) guidelines state that EMS providers should have a stroke assessment system in place with protocols that include treatment as well as notification of the nearest stroke center hospital in hopes of delivering comprehensive specialized stroke care that also incorporates rehabilitation. The primary objectives are airway management, cardiovascular support, and transport to the closest facility prepared to care for acute stroke patients (Powers et al., 2018). Hospitals can be given designations by JCAHO as an acute stroke ready hospital (ASRH), a primary stroke center (PSC), a thrombectomy-capable stroke center (TSC), or a comprehensive stroke center (CSC). Each certification has designated requirements and hospitals must apply and be reviewed for initial certification as well as continued certification or renewal. An ASRH must have an acute stroke team available 24 hours a day, initial evaluation by an Emergency Department (ED) physician, nurse practitioner (NP) or physician’s assistant (PA), a neurologist available in person or via telemedicine 24 hours a day, neurosurgical services available within 3 hours, a transfer protocol established with at least one PSC or CSC, the ability to administer IV tPA and then transfer the patient safely to another facility, and meet three inpatient and 2 outpatient stroke clinical performance measures (CPMs). A PSC must have all of the above plus an initial evaluation by an ED physician, a designated unit or group of beds for acute care of stroke patients, the ability to manage a patient after receiving IV tPA, neurosurgical services within 2 hours with 24/7 operating room availability for neurosurgical services, and meet eight core stroke CPMs. A TSC must have all of the above, as well as completed at least 15 thrombectomies over the last 12 months, a dedicated neuro-intensive care unit or beds available 24/7, magnetic resonance imaging (MRI), computed tomography angiography (CTA), magnetic resonance angiography (MRA), and catheter angiography available 24/7, ability to perform and manage mechanical thrombectomies and intra-arterial (IA) thrombolytics, and an additional 5 ischemic hemorrhagic comprehensive stroke CPMs. Finally, a CSC must demonstrate all of the above as well as treatment of 20 SAH cases caused by aneurysm annually, including 15 endovascular coiling or microsurgical clipping procedures, administer IV thrombolytic therapy 25 times annually, neurologist and neurosurgical services accessible 24/7 in person with written call schedule, ability to perform stenting of carotid arteries or CEA procedures, and a total of 8 core and 10 comprehensive stroke CPMs. Each category also has specific education requirements for providers, nurses and staff caring for acute stroke patients. Certification reviews range from one reviewer for one day in ASRHs to two reviewers for two days in CSCs (JCAHO, 2018a).

            Guidelines recommend the use of supplemental oxygen in acute stroke care only if the patient’s oxygen saturation is less than 94%. Hypotension and hypovolemia should be corrected to help support optimal organ function by maintaining systemic perfusion, but high-dose albumin or hemodilution by volume expansion is not recommended. Blood pressure should be carefully lowered to below 185/110 prior to IV fibrinolytic therapy being initiated using labetalol (Trandate), nicardipine (Cardene), clevidipine (Cleviprex) or similar. If no fibrinolytic therapy or endovascular procedures are possible, there is no benefit to initiating antihypertensives within the first 48-72 hours after the initial stroke as long as blood pressure is below 220/120. If above 220/120, it might be reasonable to lower the blood pressure 15% in 24 hours. Sources of hyperthermia (temp > 38C) should be identified and treated and antipyretics should be given to lower the temperature to normal range. Hyperglycemia should be treated to a range ot 140-180 mg/dL, and hypoglycemia below 60 mg/dL should also be treated. In fact, the only laboratory test recommended prior to administration of IV tPA in an acute stroke patient is a serum blood glucose check. (Powers et al., 2018). Otherwise, the emergency care of a stroke patient also includes circulatory assessment (with chest compressions if necessary), airway assessment (and management if necessary), and breathing assessment (with ventilatory support if necessary) just as in any other medical emergency. A full history and physical exam, including a full neurological exam, should be completed quickly on any suspected stroke patient upon arrival to the emergency department. This includes a history of risk factors, what signs or symptoms are present and exactly when they began (if known). The physical and neurological exam should include checking the patient’s alertness, comprehension, coordination, balance, sensation, strength, speech, and vision. A quick check for an audible carotid bruit should also be included (NHLBI, n.d.). In an ASRH, this initial full evaluation should be completed and documented by an ED physician, NP, or PA, but in a PSC, TSC, or CSC hospital it should be completed and documented by the ED physician. A neurologist is available 24/7 in a CSC hospital, but oftentimes completed via telemedicine in other lower level hospitals, even PSC and TSC hospitals (JCAHO, 2018a). A class strong recommendation from the ASA guidelines (2018) is that hospitals develop a stroke protocol for patient evaluation and treatment by a specified Stroke Team. A moderate recommendation states that telestroke evaluation can help with triage and accurate decision making for IV tPA in stroke patients. A weaker recommendation based on nonrandomized data is that IV tPA administration within a telestroke network is just as beneficial and safe as when it is done within a stroke center hospital (Powers et al., 2018). Teleneurology has been shown to be a cost-effective solution to provide stroke neurology expertise to every patient, regardless of where they may present to obtain care. It has been shown to result in significant improvement in both short term and long term clinical outcomes and decreased disparities in quality of care (Bowen, 2016).

An initial evaluation of a potential ischemic stroke patient should also include a rating using a stroke severity scale, such as the National Institutes of Health Stroke Scale (NIHSS) (Powers et al., 2018). The NIHSS was developed first in 1983 to assess the neurological deficits present post-stroke, modified last in 1992, and takes approximately seven minutes to complete. It includes 11 items and produces a final score between 0 and 42. The higher the score, the worse the deficits. It assesses the patient’s level of consciousness, gaze palsy, visual fields, facial palsy, bilateral upper extremity strength, bilateral lower extremity strength, limb ataxia, sensation, extinction/neglect/inattention, dysarthria, and language. A provider should be certified and trained to administer the NIHSS properly (Schienfeld, Erdfarb, Krieger, Bhupali and Zampolin, 2016). For SAH patients, ASA (Hemphill et al., 2015) and JCAHO (2018b) recommend the Hunt and Hess Scale for initial evaluation, and for ICH patients the ICH score. These should be completed prior to any surgical intervention to serve as a baseline measure and help inform prognosis as well as facilitate effective communication between providers and facilities regarding patient severity and condition. The Hunt and Hess Scale ranges from 1 (asymptomatic, mild headache, slight nuchal rigidity) to 5 (decerebrate posturing, coma). The ICH score takes into account the patient’s glasgow coma score (GCS), age, volume of ICH, and whether there exists an infratentorial origin or an intraventricular hemorrhage on imaging into a numerical value ranging from 0-6, with a higher score indicating a worse prognosis or higher expected mortality rate (Hemphill et al., 2015; JCAHO, 2018b)

In addition to the above scales which are used to initially evaluate a patient, two other commonly used stroke scales are utilized later to assess any residual or chronic deficits. The modified Rankin Scale (mRS) was originally introduced in 1957 by Dr John Rankin. It is an interview-style evaluation that can be completed in person or over the phone. It is traditionally done at 90 days after the stroke in most cases and takes approximately two minutes to complete. A score ranges from 0, which indicates no residual symptoms, to a maximum score of 6, which indicates the patient is deceased as a direct result of the stroke. A mRS of 0-2 indicates a patient who is functionally independent. Another commonly used disability tool is the Barthel Index (BI), which was first published in 1965 and is used similarly to the mRS. It is either observational or interview-style tool that can be completed with a family member or caregiver. It assesses a patient’s ability to complete 10 activities of daily living (ADLs) with a total score ranging from 0-100. The BI includes feeding, bed to chair and back, personal care/hygiene, getting on/off the toilet, bathing, walking, going up/down stairs, dressing, control of bladder, and control of bowels. A higher score correlates with a greater level of functional independence (Schienfeld, Erdfarb, Krieger, Bhupali and Zampolin, 2016).

After a complete history and physical exam, if a stroke is suspected the next step in evaluation is typically imaging studies. We will briefly discuss the imaging studies commonly ordered in stroke patients, as well as their positive and negative features. A computed tomography (CT) scan without contrast is the most common imaging study ordered initially in suspected stroke patients. This study is very quick, widely available, and allows for the radiologist and neurologist to reliably rule out a hemorrhage. Disadvantages of a noncontrast CT are the high dose of radiation delivered during the exam, the lack of reliability in detecting an early infarct core, and the ability to detect stroke via CT scan varies among radiologists and can be affected by the size and acuity of the stroke as well as the window and level settings (Powers et al., 2018). A noncontrast CT can be used to determine a patient’s Alberta Stroke Program Early CT Score (ASPECTS), which is used as a criterion for certain treatment options and can help predict stroke severity functional independence. A scale from 0-10, a lower score indicates a more pervasive and severe stroke. For more accuracy, perfusion or diffusion-weighted studies can also be used to calculate a patient’s ASPECTS (Schroder & Thomalla, 2017). Recently, mobile CT scanners have been constructed to potentially reduce time to treatment (by up to ~42 minutes) by scanning potential stroke patients en route to the hospital in what look like large ambulances equipped with a CT scanner inside. CT angiography (CTA) creates a three dimensional (3D) reformation of a patient’s entire intra- and extracranial circulation from the aorta to the Circle of Willis secondary to a timed, rapid injection of iodinated IV contrast in less than 60 seconds. The exposure to contrast is not without risk however, and patients with a known allergy to iodine or iodinated contrast or renal insufficiency (glomerular filtration rate [GFR] less than 30) should not receive contrast. A CTA can show major artery occlusion and also uncover a “spot sign”, which indicates active bleeding and can be predictive of hematoma expansion. CT perfusion studies use the same process as the CTA above, but with the addition of specialized computer software that then determines the mean transit time to establish a penumbra (an area of brain tissue at risk for hypoxic damage but still currently salvageable). The disadvantages of a CT perfusion study includes the same aforementioned radiation exposure and contrast administration as well as the expensive software needed to process the images (Franco, 2018). The ASA guidelines state that a serum creatinine is not necessary before performing a CTA on an acute stroke patient with no history of renal impairment (Powers et al., 2018).

Magnetic resonance imaging (MRI) scans are also commonly used to evaluate stroke patients. They are considered by some to be superior to CT scans in the acute phase, expose the patient to significantly less radiation, and are recommended by the American College of Radiology. However, they take longer than CT scans to complete and thus have the risk of delaying treatment. MRI machines are also generally less available than CT scanners. The small area inside the machine commonly causes patients discomfort and anxiety related to claustrophobia, and there are several contraindications to MRI scans (presence of certain aneurysm clips, pacemakers, defibrillators, stimulators, and shrapnel or other metal fragments in the eyes). They are recommended in cases of uncertain diagnosis, considered more sensitive in TIA cases, and the American Academy of Neurology officially recommended an MR diffusion weighted study in the first 12 hours after stroke symptoms develop as they found them more useful than CT scans. However, the general consensus is that if waiting to get an MRI scan will delay treatment than a CT scan is preferred. MRI diffusion weighted images (DWI) take approximately 10 additional minutes to complete and have been shown to detect early ischemic changes with better accuracy (99% sensitivity and 92% specificity). An MR perfusion study, similar to a CT perfusion study, utilizes a contrast agent (gadolinium) and a rapid series of MR images to detect a diffusion/perfusion mismatch (penumbra) in patients that may be beyond the 3-4.5 hour window since symptoms started. This may allow providers additional information regarding the potential utility of IV thrombolytic therapy and/or interventional thrombectomy procedures. Patients with a gadolinium allergy should not receive gadolinium contrast, as well as pregnant patients or those with renal insufficiency. If unable to perform MR perfusion with IV contrast, arterial spin labeling can visualize brain perfusion by magnetically labeling (inverting) arterial blood protons. MR angiography can be used to image the vessels in the neck using IV contrast. It helps detect athersclerotic lesions in the neck and head with increased reliability (sensitivity 85%) compared to a standard MRI but less than a CTA. It can be used to visualize carotid or vertebral artery dissections or fibromuscular dysplasia. A “time-of-flight” MRA is able to image the major arteries of the head without the use of IV contrast. If it is unknown whether a patient has MRI-compatible aneurysm clips, a pacemaker, metal eye fragments or other contraindication to receiving an MRI scan, an xray of the head, chest, and abdomen can be done to help determine eligibility (Franco, 2018).

Regarding imaging studies, the ASA guidelines (2018) recommend all suspected stroke patients receive brain diagnostic imaging, usually a noncontrast CT scan. Ideally, at least 50% of stroke patients should receive this within 20 minutes of arrival at the ED. A noninvasive intracranial vascular study is strongly recommended during the initial imaging evaluation of a stroke patient if they are believed to be a candidate for endovascular treatment as long as this does not delay IV tPA administration. A moderate recommendation is to include the carotid and vertebral arteries in this initial imaging study at the same time, although as previously mentioned the evidence supporting emergent or urgent carotid endarterectomy procedures post-stroke is not well established. Perfusion imaging should also not delay IV tPA administration. In fact, the ASA found no benefit to performing perfusion images (CT or MRI) or DW-MRI in acute stroke patients that are within the 6 hour time window from symptom onset for the purpose of patient selection for mechanical thrombectomy procedure. These imaging studies are strongly recommended in the group of acute stroke patients with LVO occlusion in the anterior circulation that are between 6-24 hours from symptom onset as they can be very helpful in treatment decision making in this group (Powers et al., 2018).

Acute Management: Hemorrhagic Strokes

            Similar to ischemic stroke, the ASA (Hemphill et al., 2015) has published guidelines regarding the treatment of ICH. A baseline severity score (ICH Score if depressed level of consciousness, or NIHSS if patient is conscious) and rapid neuroimaging to define the problem are just as important for hemorrhagic stroke patients as they are in ischemic stroke patients. Vitals signs as well as a complete history and targeted physical exam will help direct immediate care. A severely hypertensive patient (SBP 150-220) with a hemorrhagic stroke needs antihypertensive medication to reduce it safely to 140 to help limit the bleeding, and consistent control of blood pressure going forward. As with patients with ischemic strokes, blood glucose should be monitored and treated to avoid hyperglycemia or hypoglycemia. Coagulation factors and platelet count should be ordered to assess for coagulation factor deficiency, thrombocytopenia, or other abnormalities so these things can be addressed. Coagulation factor deficiencies should be treated with factor replacement therapy, and thrombocytopenia with platelets. Patients taking Vitamin K antagonists (warfarin [Coumadin]) with elevated INR should receive vitamin K as well as fresh frozen plasma [FFP] or other therapy to replace vitamin K–dependent factors. Recently prothrombin complex concentrates (PCCs), the activated PCC factor VIII inhibitor bypassing activity (FEIBA), and recombinant activated factor VIIa (rFVIIa) have emerged as treatment options. In patients taking newer anticoagulation medications such as dabigatran (Pradaxa), apixaban (Eliquis), or rivaroxaban (Xarelto) without clear reversal agents, the ASA recommends evaluation of the activated partial thromboplastin time (aPTT) and prothrombin time (PT) and consultation with a hematologist.  Often FEIBA, other PCCs, or rFVIIa as mentioned above may be considered. All ICH patients should receive treatment with sequential compression devices (SCDs) to prevent deep vein thrombosis (DVTs) starting the day of hospital admission. Clinical seizures should be treated with antiseizure medications as well as patients with a change in mental status who are found to have electrographic seizures on EEG. ICH patients should be cared for in an intensive care unit (ICU) or a dedicated stroke unit with physicians and nurses trained in their specialized care. If deteriorating neurologically, patients with cerebellar hemorrhage and subsequent brainstem compression and/or hydrocephalus related to ventricular obstruction should have spinal fluid diversion with ventriculostomy or lumbar drain and/or the hemorrhage removed surgically as soon as possible (Hemphill et al., 2015). If an AVM is found to be the cause of the patient’s stroke, there are a few options. The AVM can be removed surgically or a liquid tissue adhesive can  be injected into the AVM to block blood flow and stop the bleeding. Radiation can also be used to treat AVMs if they are found non-emergently and are not actively bleeding (Franco, 2018; NHLBI, n.d.; NINDS, 2018).

            SAH are most commonly associated with aneurysm rupture or leak. An aneurysm may be treated surgically using microvascular clips placed at the base or neck of the aneurysm to prevent future leaking by blocking it off from blood flow. The risks are high for this procedure, as it requires open brain surgery to place the clips, but is less likely to recur and need to be repeated if done properly. Coil embolization uses an access catheter placed in the groin to embolize an aneurysm with detachable platinum coils. It is less invasive than clipping, but may need to repeated in the future and is more likely to lead to the complication of vasospasms postoperatively (Franco, 2018; NHLBI, n.d.; NINDS, 2018). Three main randomized, prospective studies have compared both techniques. Of these, the International Subarachnoid Aneurysm Trial (ISAT) found a statistically significant improvement in survival rates at 12 months with coiling, and has thus strongly influenced the surgical patterns in the last 15 years since initial publication in the early 2000s. The most recent guidelines published by the ASA regarding aneurysmal SAH also recommended coiling over clipping when both are feasible. These procedures can also be done preventatively depending on the location of the aneurysm. Larger aneurysms in the posterior circulation have been shown to be more prone to rupture and surgeons are more likely to recommend prophylactic surgical treatment if these are found non-emergently. The severity of the hemorrhage and the patient’s age remain the two most important prognostic factors in aneurysmal SAH patients. (Grasso, Alafaci, & Macdonald, 2017). A third surgical option for larger and more difficult to treat aneurysms is placing a stent-like flow diversion device via an endovascular catheter (NINDS, 2018).


Acute Management: Fibrinolytic Therapy and Thrombectomy for Ischemic Strokes

            Tissue plasminogen activator (tPA) was first approved in 1995 by the Food and Drug Administration (FDA), and remains only approved for intravenous use (Spiotta et al., 2015). As previously stated, the patient blood glucose should be checked prior to initiation of IV tPA and corrected if necessary. Baseline troponin and an echocardiogram (ECG) are recommended as well but not required and should not delay administration.  IV tPA is dosed at 0.9 mg/kg with a max of 90 mg and given over 60 minutes. The initial bolus should account for 10% of the patient’s total dose and be given over the first minute. Treatment is time dependent and thus should be initiated as soon as possible. In acute stroke patients that are within 3 hours of symptom onset, IV fibrinolytic therapy with tPA is recommended in patients that are at least 18 years old with severe or mild but disabling stroke symptoms present. There is also a strong recommendation based on level B evidence that acute stroke patients within 3-4.5 hours of initial symptom onset that otherwise meet criteria should be treated with IV tPA as well.  The additional criteria suggested for patients within the 3-4.5 hour window includes the same criteria above, as well as:

  • Age 80 or less
  • No history of prior stroke
  • No history of diabetes mellitus
  • NIHSS of no more than 25
  • Not taking an oral anticoagulant
  • Without imaging evidence of ischemic injury involving more than one third of the MCA territory.

IV tPA should not be given with abciximab (Reopro) or within 24 hours of low-molecular weight heparin (LMWH) such as enoxaparin (Lovenox). There is no need to check coagulation studies or platelet count prior to administration unless there is suspicion that these are abnormal. Risks and benefits of IV thrombolytic therapy should be reviewed with the patient and family or caregivers extensively, and staff and providers should be prepared and fully capable of managing any emergent adverse effects such as bleeding or angioedema. Treatment should be stopped immediately and a head CT obtained stat if the following symptom changes occur during or after IV tPA: severe headache, acute hypertension, nausea/vomiting, or a worsening or changed neurological exam. IV Tenecteplase can be considered as an alternative in patients with no major intracranial occlusion and only minor neurological impairment. It is recommended to avoid other treatments that could cause bleeding issues, such as nasogastric (NG) tubes, urinary catheters, and intra-arterial pressure catheters if they can be safely avoided. After administration of IV tPA, the patient should be monitored closely for changes in neurological status, with blood pressure checks and neurological exam every 15 minutes for the first two hours, then every 30 minutes for 6 hours, then hourly until 24 hours after initial administration of the medication. IV tPA is contraindicated in patients with acute intracranial hemorrhage on CT scan, a history of severe head trauma in the last three months, symptoms consistent with infective endocarditis or aortic arch dissection, or with coagulopathy (platelets <100 000/mm3, INR >1.7, aPTT >40s, or PT >15s).  IV tPA may be potentially harmful in patients with a history of acute ischemic stroke in the last three months, any history of ICH, signs/symptoms of SAH, a structural GI malignancy, a recent bleeding event within 21 days, taken a thrombin inhibitor/factor Xa inhibitor within 48 hours, an intra-axial intracranial neoplasm or intracranial/intraspinal surgery in the last three months. Neuroimaging should be repeated approximately 24 hours following administration of thrombolytics prior to starting antithrombotic agents orally (Powers et al., 2018).

            A disadvantage of IV thrombolytic therapy is its lack of effectiveness in clearing large vessel occlusions. This, in combination with its very narrow window of availability, lead researchers to continue developing stroke treatments that would improve upon these shortcomings. Intra-arterial injections of urokinase and prourokinase were developed and tested for safety and effectiveness in the PROACT I and II trials. PROACT II was published in 1999 and was a randomized trial testing recombinant prourokinase versus placebo in angiographic-documented proximal MCA occlusions. The trial showed increased recanalization and improved outcomes with acceptable complication rates but the medication did not receive FDA approval. It does continue to be used, along with intra-arterial tPA and abciximab (Reopro), in this method as an off-label usage (Spiotta et al., 2015).

            Following intra-arterial injections, research then focused its attention on interventional endovascular thrombectomy devices and approaches to disrupt or remove the clot. The first attempt was a “J” or “C” shaped microwire for clot disruption. In 2005 the flexible intracranial balloon catheter was introduced. Although initially designed for vessel angioplasty but eventually was used for mechanical thrombectomy by repeated angioplasty of the clot itself. Intracranial stents were developed next, and allowed for a partially deployed stent, such as the Enterprise vascular reconstruction device, that could either be placed permanently or partially deployed and retrieved, creating clot disruption and partial flow restoration. The downside of permanent stent deployment is the lifelong need for dual antiplatelet therapy. All of the above therapies are still considered off label and are not currently FDA approved (Spiotta et al., 2015).

            In 2004, the Merci retriever device became the first device cleared by the FDA for mechanical thrombectomy in acute stroke patients. It utilizes a corkscrew wire/suture tip to remove the clot en bloc. Revascularization rates range from 48-68%, and up to 36% of patients in initial studies reported an mRS of 0-2 at 90 days. The Outreach distal access catheter (DAC) was approved in 2010 and provided buttressing access for Merci and similar devices. It provides more stable access and increased aspiration power. Then, in 2008 the Penumbra aspiration system was introduced. The Penumbra macerates the clot with a separator which is repeatedly advanced into and withdrawn from the clot, all under direct suction. It utilizes a relatively large bore catheter, versus the Merci’s microcatheter. Studies of the Penumbra indicated revascularization rates between 82-87% with up to 41% of patients reporting an mRS of 0-2 at 90 days. The Penumbra studies also reported slightly lower complication rates than the Merci. Over time, the catheters used with the Penumbra device have improved, decreasing average procedure time. An advantage of the Penumbra device is that once the catheter has reached the target vessel, separator clot maceration can be performed without having to re-access (additional passes) as is the case with the Merci device. In 2012, Penumbra introduced their Max series, which allows direct aspiration without a separator, decreasing the cost, and larger inner diameters at the distal and proximal end of the catheter, increasing the aspiration power. The Penumbra 3D separator attempts to engage the clot at the center of the vessel lumen with four intraluminal chambers (Spiotta et al., 2015).

            Finally, the most recent development in thrombectomy devices is the stent retriever device, such as the Solitaire and Trevo Pro. These are now the most commonly used, and they are based on the Enterprise stents used early on that were partially deployed. These stents are removable, negating the need for dual antiplatelet therapy long term. The stents are opened from within the center of the thrombus and suction is applied during retrieval, or they can be used with a Penumbra system for retrieval. Studies have shown the recanalization rates are better than the Merci device (61% and 86% for Solitaire and Trevo respectively), as are the Rankin scores (mRS 0-2 @ 90 days, 36% and 40% for Solitaire and Trevo respectively). Future research is looking at the use of ultrasound vibration to facilitate thrombolysis, designed to be used with intra-arterial tPA (Spiotta et al., 2015). The ASA does not recommend devices to augment cerebral blood flow, neuroprotective agents such as magnesium, or transcranial near-infrared laser therapy (Powers et al., 2018).

            One of the largest advantages to a mechanical thrombectomy procedure is that it has been proven safe in acute stroke patients within six hours of symptom onset. ASA guidelines (2018) stipulate that in order to qualify for mechanical thrombectomy with a stent retriever, an acute stroke patient should meet all of the following criteria:

  • mRS pre-stroke of 0-1 (no significant disability present)
  • Occlusion of the internal carotid artery or segment 1 of the MCA
  • NIHSS score of 6 or greater
  • At least 18 years of age
  • ASPECTS of 6 or greater (Powers et al., 2018).

With all of these treatment options for acute ischemic stroke available, the choice of how to treat a patient is oftentimes difficult to assess. In an effort to ascertain the most reliable and safe treatment available, numerous studies have been done to both prove the efficacy and safety of stent retrievers for mechanical thrombectomy in acute ischemic stroke patients. In 2015, five randomized clinical trials were all published in the same year attempting to establish the superiority of mechanical thrombectomy procedures for selected patients with acute ischemic strokes. The first, MRCLEAN, was conducted in the Netherlands. 500 patients were enrolled, 89% of which underwent IV tPA treatment and some also underwent intra-arterial tPA (10%). The treatment group (n= 233) underwent thrombectomy within six hours of symptom onset. 190 of the total 195 thrombectomy procedures were done with stent retrievers. 32.6% of the treatment group achieved functional independence (mRS 002 at 90 days) versus just 19.1% of the control group (Berkhemer et al., 2015). Two additional studies were published just two months later. The ESCAPE trial was conducted at multiple sites worldwide, with a slightly longer time window for completing thrombectomy procedures (twelve hours since symptom onset). Medical treatment was again compared with thrombectomy treatment, and in this trial stent retrievers were recommended but not required, and they were used in 130 of the 151 thrombectomy procedures completed (100 of which were the Solitaire device specifically). Intravenous tPA was given to roughly 75% of patients in both the treatment and control groups. A key to note in this trial is that researchers chose to exclude patients with a large infarct score on imaging, which was not an exclusion criteria in MRCLEAN. Functional independence was recorded for 53% of the treatment group, versus just 29.3% of the control group. An added bonus was a secondary outcome of reduced mortality rates in the treatment group versus the control group as well (10.4% vs 19%) (Goyal et al., 2015). The EXTEND IA trial was published the same month but was conducted in Australia and New Zealand. All patients in this trial received IV tPA treatment, and all thrombectomies were done using the Solitaire stent retriever within six hours of symptom onset. Patients were excluded based on infarct core size as well as perfusion mismatch on imaging. Only 35 patients were enrolled for each group, and the treatment group had significantly higher rates of functional independence at 90 days (71%) versus the medical group (40%), a secondary outcome. The coprimary outcomes (reperfusion rates on imaging and early neurological improvement on NIHSS) both showed statistical improvement with thrombectomy procedure (Campbell et al., 2015). Then three months later, two additional studies were published. The REVASCAT trial was conducted in Spain using the Solitaire stent retriever device. 206 patients were enrolled who could be treated within eight hours of symptom onset with an ASPECTS score of at least 6 or 7 (depending on imaging modality, to exclude those patients with large infarct cores). 43.7% of thrombectomy patients achieved functional independence at 90 days, versus just 28.2% of the control group. Similar to other studies, roughly 75% of both the control and treatment groups received IV tPA in this study (Jovin et al., 2015). Finally, the SWIFT PRIME trial was also published in June of 2015. All patients in this New York-based study received IV tPA, patients were again excluded for large infarct cores, and the Solitaire thrombectomy device was used exclusively. 196 patients were enrolled in the study, and 60% of the treatment group achieved functional independence at 90 days, versus just 35% of the control or medical group (Saver, 2015).

A meta-analysis of 1287 patients from the five above studies was then conducted and published, and concluded that in cases of proximal occlusions of either of the anterior arteries (MCA or the ICA), thrombectomy procedure led to significantly less disability at 90 days versus standard medical treatment alone. This difference was even present in three high-risk groups of patients: those over the age of 80, those more than 300 minutes (5 hours) out from symptom onset, and those patients that were found not eligible for IV tPA treatment. Regarding safety, when combined the five studies showed no significant increase in mortality rate, risk of parenchymal hematoma or symptomatic ICH. One note, the meta-analysis and many of these studies were at least partially funded by Covidien/Medtronic, the company that manufactures the Solitaire thrombectomy device, leading to some healthy skepticism regarding their inherent bias (Goyal et al., 2016). Another group combined the above five studies in another meta-analysis to determine the ideal timing in which to consider thrombectomy procedure. Their analysis determined that the benefits of thrombectomy procedure versus medical treatment alone diminished after just over seven hours (seven hours and 18 minutes, to be exact) from symptom onset to anticipated arterial puncture (not to conclusion of procedure) (Saver et. al., 2016).

The following year, two additional studies were published regarding thrombectomies, and whether or not IV tPA was a necessary adjunct or simply an added expense. Another meta-analysis, this time of 13 studies, some including multiple trials, was published to review cases of thrombectomy alone (n=236) versus thrombectomy following IV tPA (n=681). They concluded that the thrombectomy group resulted in 45.8% of patients reporting functional independence at 90 days, versus 49% in the combination group. Although this difference was statistically non-significant, the authors found it important. Mortality rates were 12.5% in the combination group versus 17.4% in thrombectomy only group, which was a significant difference. They also found a higher rate of successful recanalization in the combination group as well as less “passes” required during the procedures, and no increased risk of symptomatic ICH. The authors commented on the fact that the trials used for this analysis did not randomize patients to receive the IV tPA treatment, and suggested further randomized controlled clinical trials in the future (Mistry et al., 2017). Another group analyzed two older studies, the SWIFT trial and the STAR trial published in 2012 and 2013 respectively, to explore the same question. This pooled analysis used the records of 291 patients who had undergone mechanical thrombectomy with the Solitaire device within eight hours of symptom onset, 160 of which had also received IV tPA treatment prior to the procedure. When comparing the combination patients against the thrombectomy-only patients, the authors found a decreased risk of symptomatic ICH (1.1% vs 3.8%) and an increased rate of functional independence at 90 days (57.7% versus 47.7%) in the combination group, but these findings did not reach the level of statistical significance. They did comment that vasospasm was more common in the combination group who received IV tPA (Coutinho et al., 2017).

The benefits are “uncertain” but the ASA states it is reasonable to also proceed with thrombectomy in “carefully selected patients” with an occlusion in segment 2 or 3 of the MCA, the anterior cerebral artery, vertebral artery, basilar artery, the posterior cerebral artery, with a pre-stroke mRS of >1, an ASPECTS <6, or an NIHSS <6. If the patient presents with symptoms present for 6-16 hours, they also recommend thrombectomy procedure if the patient is able to meet DAWN or DEFUSE3 criteria, or 16-24 hours if the patients meets the DAWN criteria (Powers et al., 2018). The DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo (The DAWN Trial) published in 2018 showed that among the 207 patients enrolled in the study, the study group who underwent thrombectomy had significantly improved functional outcomes based on mRS scores, with no significant difference in mortality or hemorrhage complication rates. The enrolled patients had stroke symptoms lasting between 6 and 24 hours secondary to acute occlusion of the intracranial ICA or proximal MCA. All patients had to have an NIHSS of at least 10. If 80 or older, they also had to have an infarct volume, as measured by DW-MRI or perfusion CT scan, of less than 21 mL. If under the age of 80, they had to have an infarct volume of less than 31 mL. If under 80 and with an NIHSS of 20 or higher, they had to have an infarct volume between 31 and 50 mL (Nogueira et al., 2018). The Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke (The DEFUSE3 Trial) enrolled 182 patients with proximal MCA or ICA occlusions. The time limit for symptom duration for this study was between 6-16 hours since last known well. Patients were required to have an initial infarct volume (ischemic core) of less than 70 ml, a ratio of volume of ischemic tissue to initial infarct volume of 1.8 or more, and an absolute volume of potentially reversible ischemia (penumbra) of 15 ml or more. Both studies utilized the same RAPID software to help calculate volumes based on DW-MRI or perfusion CT scans (Albers et al., 2018).

Acute Management: Post Procedure

A blood pressure of less than 180/105 should be maintained for at least 24 hours following either administration of IV fibrinolytics or an endovascular thrombectomy. Blood pressure over this during the first 24 hours should be treated to avoid hemorrhagic conversion. In patients not treated with endovascular procedures or IV tPA, blood pressure may be allowed to increase to as high as 220/120 for the first 48-72 hours after an acute ischemic stroke. Over this, it is reasonable to attempt to medicate to decrease the blood pressure by 15% within 24 hours. Vasodilatory agents are not recommended. If the blood pressure consistently remains over 140/90, it is safe and reasonable to initiate or restart an antihypertensive prior to discharge. Cardiac monitoring is recommended for at least 24 hours to rule out atrial fibrillation or another arrhythmia. In stroke patients with a diagnosis of Afib, anticoagulation therapy should be started within 4-14 days. Regular skin assessments and optimal skin care (regular turning, good hygiene, specialized mattresses/wheelchair cushions) are important to maintain skin integrity in stroke patients that may have limited mobility. A dysphagia screen should be done prior to allowing any oral intake in a stroke patient, preferably done by a speech and language therapist (SLT). An enteral diet should be started within 7 days of admission. If the patient has significant dysphagia, then an nasogastric (NG) tube (for short term dysphagia) or a percutaneous endoscopic gastrostomy (PEG) tube (for longer term dysphagia) should be placed to achieve this. Nutritional supplementation and oral hygiene are reasonable. Daily aspirin, adequate hydration, and SCDs are recommended in immobile patients to reduce the risk of deep vein thrombosis (DVT). For non-cardioembolic strokes, urgent anticoagulation is not recommended but dual antiplatelet therapy with aspirin and clopidogrel is recommended for the first 21 days (usually started with 24-48 hours if no tPA, 48-72 hours if the patient received tPA), followed by clopidogrel alone until 90 days. They found no benefit to prophylactic antibiotics, and routine urinary catheter placement should be avoided. Seizures, if they occur in acute stroke patients, should be treated as they would otherwise, with anti-seizure medications chosen based on the patient’s individual situation. Anti-seizure medication should not be given prophylactically. (Powers et al., 2018).

Symptomatic ICH (sICH) occurs in 2-7% of acute stroke patients after receiving IV tPA treatment. The diagnosis is a combination of radiological findings as well as neurological exam changes. It typically occurs within 36 hours of tPA administration. The neurological exams following an acute stroke treated with IV tPA are key, with thorough and complete documentation of any changes in the patient’s NIHSS. Once identified, the patient should be moved immediately to an ICU or back to the stroke unit if not already there. Management includes cardiovascular/respiratory support if needed, blood pressure management (ideal range varies and is still unclear), close neurological monitoring, prevention of hematoma expansion, and treatment of elevated intracranial pressure (ICP) and other complications that arise from the hemorrhage including seizures, as with any spontaneous ICH (see previous section on management of ICH). Based on the current research, most providers are immediately ordering/sending a fibrinogen level and empirically transfusing with 10 U cryoprecipitate and anticipate giving more cryoprecipitate as needed to achieve a fibrinogen level of ≥150 mg/dL. Platelets may also be transfused, especially if the platelet level is < 100,000/μL. In patients previously on warfarin, FFP, PCCs, and/or vitamin K may also be considered. Two antifibrinolytic agents, aminocaproic acid and tranexamic acid, may also be considered, but further research is needed to know when they are best utilized. They may be helpful in patients who refuse blood products as they work by inhibiting proteolytic enzymes such as plasmin, which are known to mediate the action of alteplase. Due to complications, rFVIIa should be avoided in sICH (Yaghi et al., 2017)

Other common complications following an acute stroke include cerebellar or cerebral edema, which may lead to obstructive hydrocephalus, especially in cerebellar infarcts. Ventriculostomy is the treatment of choice in this instance, according to the ASA guidelines, and potentially a decompressive craniectomy if necessary. If short term spinal fluid diversion is needed postoperatively (as is common in SAH patients) a lumbar drain could also be considered. Patients with large supratentorial infarcts are also at increased risk for cerebral edema leading to increased ICP. This risk should be communicated with the patient and family and treatment and care options discussed early on. Measures should be taken to reduce risk for edema, and patients should be monitored closely for sign or symptoms. Osmotic therapy and brief moderate hyperventilation (PCO2 target 30-34) are medical treatments that are reasonable for cerebral or cerebellar edema, but hypothermia, barbiturates, and corticosteroids should be avoided. Major infarcts should be transferred to a care facility with neurosurgical expertise if needed. Decompressive craniectomy is also reasonable to reduce mortality in stroke patients under the age of 60 with a unilateral MCA infarct with continued neurological deterioration for 48 hours after acute stroke. Over the age of 60, a craniectomy “may be considered” as it has still been shown to reduce mortality by as much as 50% in this older group, but has less favorable outcomes on functional recovery. The ASA specifically recommends stroke patient education, provided to both the family and the patient, as well as allowing the patient the opportunity to talk about the impact of the illness on their lives (Powers et al., 2018). As previously found, many of these ASA guidelines are also primary stroke CPMs published by the Joint Commission (JCAHO, 2018b).

A common complication following surgical treatment for an aneurysm and resultant SAH is vasospasm and secondary or delayed cerebral ischemia. Cerebral vasospasm occurs in 70% of the patients following aneurysmal SAH and leads to symptomatic brain ischemia in 30% of the cases. Oral nimodipine, a dihydropyridine calcium channel antagonist, should be started after surgery (60 mg every 4 hours) for a total of 21 days, after which the risk of this particular complication decreases. Previously, prevention of this complication was also accomplished via “Triple-H” therapy, which included hypervolemia, hemodilution, and induced hypertension. All but the induced hypertension have been studied individually however and fallen out of favor as they failed to show any benefit, and may even carry risk. Induced hypertension and euvolemia is the new recommendation, with isotonic crystalloid the intravascular fluid of choice. Cerebral vasospasm monitored using transcranial dopplers is also reasonable for patients at risk or with a known history. Treatments currently being investigated include magnesium, statins, endothelin receptor antagonists, Tirilazad, erythropoietin, and glyburide, but while these options all showed promise in preclinical testing none have yet to show significant impact in phase III trials (Grasso, Alafaci, & Macdonald, 2017).

Finally, a note regarding teamwork, protocols, and workflow optimization is important to include here as a final umbrella that affects all stages of care for stroke patients. The ASA recommends multiple times throughout their latest guideline that hospitals and providers develop organized protocols, designate teams in order to provide “comprehensive specialized” care to stroke patients. While these recommendations may not be as interesting to focus on as new technology, devices, and pharmaceuticals, they are exceedingly important. A German hospital conducted a study that was published in 2018 regarding the effect of two significant changes to the manner in which they care for acute stroke patients. The first change was to provide 24 hour, on-site neuroradiological service. This provided some improvement in their outcomes, but was not statistically significant. It was only when they instituted extensive workflow optimization and documentation of procedure times did they begin to see significant improvements in their door-to-image, image-to-puncture, and door-to-revascularization times, especially in patients presenting for care outside of normal business hours. And after all, time is tissue (Nikoubashman et al., 2018).


            After a stroke, there are two primary mechanisms for brain recovery. The first happens early and automatically as the circulation to an area is restored and the edema recedes. The second is termed neuroplasticity and involves neurons in the brain reorganizing their structure, function, and interconnections. While damaged neurons in the central nervous system often die and are not able to regenerate, undamaged axons have been shown to grow new nerve endings to connect to other undamaged neurons, called neuro-cortical sprouting. Also, stroke patients may be able to train their brain to perform tasks by using previously latent functional pathways. This learning is stimulated primarily by repetitive practice. Researchers are searching for ways in which this could potentially be increased or augmented with things like medications or transcranial magnetic stimulation (Palmer, (2015).

(Image courtesy of CDC, 2018)

The ASA found that roughly 70% of Medicare patients diagnosed with acute stroke utilize the medicare-covered postacute care. About 32% are sent to skilled nursing facilities for rehabilitation, 22% to inpatient rehabilitation facilities (either free-standing or within an acute care hospital) and 15% home with home health care. This means that 30% of all stroke patients covered by Medicare get no postacute rehabilitation at all, a number that has increased since the 1990s (Winstein et al., 2016). Prior to discharge all stroke patients should be screened for depression and appropriately treated if present and a formal assessment of functional ADLs, instrumental ADLs (iADLs), communication skills, and functional mobility by a clinician with expertise in rehabilitation. If they qualify, all stroke patients should receive early rehabilitation in an environment with organized interprofessional stroke care at an intensity commensurate with their tolerance and anticipated benefit. High-dose therapy within 24 hours of stroke should be avoided. Fluoxetine (or other selective serotonin reuptake inhibitors [SSRIs]) use during stroke rehabilitation to enhance motor recovery in the absence of confirmed depression is not yet well established (Powers et al., 2018; Winstein et al., 2016). The ASA Rehabilitation Guidelines (2016), recommend that stroke patients remain in an inpatient setting for their rehabilitation if they require therapy interventions from multiple disciplines (physical therapy (PT) and occupational therapy (OT) to address moderate to severe motor or sensory deficits, OT and SLT to address cognitive deficits, and SLT to address communication deficits) as well as skilled nursing care for:

  • Bowel or bladder impairment
  • Existing or increased risk for skin breakdown
  • Impaired bed mobility
  • Dependence for basic ADLs
  • Inability to manage medications independently
  • Increased risk for nutritional deficits

as well as documented need for daily provider contact to help manage:

  • Significant or multiple medical comorbidities
  • Complex rehabilitation issues such as bowel/bladder incontinence, spasticity, or orthotics
  • Acute illness
  • Pain management issues

A rehabilitation unit for acute stroke patients should be a comprehensive, evidenced-based, and multidisciplinary program that focuses on prevention of complications, medical  management, and the rehabilitation of sensorimotor impairments, upper extremity activities, cognitive or communication deficits, and transitions of care to home or to the community. It involves a sustained and coordinated effort from a team that includes the patient, the patient’s family, caregiver(s) and friends, physicians, mid level pactitioners ,nurses, PTs, OTs, SLTs, recreational therapists, psychologists, nutritionists, social workers, and others. Communication and coordination are extremely important in these environments. A PT-guided balance training program is paramount to safety if there is poor balance or an increased risk of falls documented on the patient’s physical therapy or nursing assessments or simply a decrease in the patient’s balance confidence or a fear of falls secondary to the acute stroke. When the patient is appropriate for discharge back to home, an individually tailored exercise program to gradually improve cardiovascular fitness is helpful for secondary stroke prevention (Winstein et al., 2016).

A systematic meta-review of 13 systematic reviews found that when self-care was included as a component of a rehab program post-stroke it resulted in short term (<1 year) improvements in ADLs and a decreased risk of dependence and death. In a separate study by Fryer et al., self-care was shown to increase the quality of life and self-efficacy after stroke (Riegel et al., 2017). Other complimentary treatments, such as acupuncture, are also being tested. A meta-analysis of 8 randomized controlled trials was completed, including 399 patients with post-stroke spasticity treated with acupuncture versus sham procedures in one study, and acupuncture plus PT versus PT alone in the other seven studies.  The analysis unfortunately showed no effect on clinical outcomes (as tested by the modified Ashworth Scale [mAS]) or physiologic outcomes (as tested by the H-reflex/M-response ratio) except in two trials, who were able to show a significant improvement after the first visit only (Park et al., 2014). Dysphagia, which is difficulty swallowing, is another common chronic sequelae of stroke. A systematic review of 58 studies involving over 6000 patients who underwent acupuncture treatment for their dysphagia showed that the acupuncture group was superior to the control with moderate heterogeneity, and the efficacy rate of acupuncture was 3 times that of the control group with no heterogeneity (Ye et al., 2017).

Technology is also playing a role in increasing the availability and decreasing the cost of post-stroke care and rehabilitation services. When stroke patients with chronic aphasia were treated with constraint induced aphasia therapy (CIAT, also know as intensive language action therapy or ILAT), even in a computer based format in their own home, it may help improve communication skills. Computer software can be personalized to an individual patient’s needs, and with the development of better speech recognition software to help with word choice and pronunciation, speech therapy patients can be initially trained and then tracked remotely. Exercises can then be adjusted as the patient improves. All of this happens as the patient is able to practice and work at home instead of the increased time and cost of patients travelling for their speech therapy appointments (Palmer, 2015).

If the patient has residual chronic deficits, many find that even after the acute phase they may still benefit from therapies months or years later. A combination treatment of four weeks of repetitive facilitative exercises (RFEs) and orthotics was tested within a physical therapy office on 27 stroke patients that were at least 5 months and an average of 35 months post-stroke. While this was a small sample size, all measures showed significant improvement after treatment. RFEs combine high repetition rate and neurofacilitation where trained therapists use muscle spindle stretching and skin-generated reflexes to help the patient activate and move an affected limb (Tomioka et al., 2017).


Albers, G. W., Marks, M. P., Kemp, S., Christensen, S., Tsai, J. P., Ortega-Gutierrez, S.,... Lansberg, M. G., (2018). Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. The New England Journal of Medicine, 378, doi:10.1056/NEJMoa1713973.

Benjamin, E.J., Virani, S.S., Callaway, C.W., Chamberlain, A.M., Chang, A.R., Cheng, S., ... Muntner, P. (2018, March). Heart disease and stroke statistics—2018 Update: A report from the American Heart Association. Circulation,137, e67–e492. doi: 10.1161/CIR.0000000000000558

Berkhemer, O.A., Fransen, P.S.S., Beumer, D., van den Berg, L. A., Lingsma, H. F., Yoo, A. J., ... Dippel, D. W. J. (2015) A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med, 372, 11-20.

Bowen, P. (2016). Early identification, rapid response and effective treatment of acute stroke: utilizing teleneurology to ensure optimal clinical outcomes. MedSurg Nursing, 25(4) 241-243.

Campbell, B.C., Mitchell, P.J., Kleinig, T.J., Dewey, H.M., Churilov, L., Yassi, N.,... Davis, S. M. (2015). Endovascular therapy for ischemic stroke with perfusion-imaging selection. The New England Journal of Medicine, 372, 1009–1018. doi: 10.1056/NEJMoa1414792.

Coutinho, J.M., Liebeskind, D.S., Slater, L., Nogueira, R. G., Clark, W., Dávalos, A.,... Pereira, V.M. (2017). Combined intravenous thrombolysis and thrombectomy vs thrombectomy alone for acute ischemic stroke: A pooled analysis of the SWIFT and STAR studies. JAMA Neurology, 74, 268–274. doi:10.1001/jamaneurol.2016.5374

Franco, J. (2018) Imaging and treatment of strokes. Radiologic technology, 89(6), 549-568.

Goyal, M., Demchuk, A.M., Menon, B.K., Eesa, M., Rempel, J.L., Thornton, J.,... Hill, M. D. (2015) Randomized assessment of rapid endovascular treatment of ischemic stroke. The New England Journal of Medicine, 372, 1019–1030. doi: 10.1056/NEJMoa1414905.

Goyal, M., Menon, B. K., Zwam, W. H., Dippel, D. W., Mitchell, P. J., Demchuk, A. M., . . . Jovin, T. G. (2016). Endovascular thrombectomy after large-vessel ischaemic stroke: A meta-analysis of individual patient data from five randomised trials. The Lancet,387(10029), 1723-1731. doi:10.1016/s0140-6736(16)00163-x

Grasso, G., Alafaci, C., & Macdonald, R. L. (2017). Management of aneurysmal subarachnoid hemorrhage: State of the art and future perspectives. Surgical neurology international, 8, 11. doi:10.4103/2152-7806.198738

Hemphill, J.C. III, Greenberg, S.M., Anderson, C.S., Becker, K., Bendok, B.R., Cushman, M.,... Woo, D. (2015). Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 46, 1-29. doi: 10.1161/STR.0000000000000069.

Jovin, T.G., Chamorro, A., Cobo, E., de Miquel, M.A., Molina, C.A., Rovira, A.,...Dávalos, A. (2015). Thrombectomy within 8 hours after symptom onset in ischemic stroke. The New England Journal of Medicine, 372, 2296–2306. doi:10.1056/NEJMoa1503780.

Meng, R., Ding, Y., Asmaro, K., Brogan, D., Meng, L., Sui, M., … Ji, X. (2015). Ischemic conditioning is safe and effective for octo- and nonagenarians in stroke prevention and treatment. Neurotherapeutics : The Journal of the American Society for Experimental NeuroTherapeutics, 12(3), 667-77. doi: 10.1007/s13311-015-0358-6.

Mistry, E. A., Mistry, A. M., Nakawah, M. O., Chitale, R. V., James, R. F., Volpi, J. J., a& Fusco, M. R. (2017). Mechanical thrombectomy outcomes with and without Intravenous thrombolysis in stroke patients. Stroke, 48, 2450–2456. doi: 10.1161/STROKEAHA.117.017320.

Nikoubashman, O., Schürmann, K., Othman, A. E., Bach, J-P., Wiesmann, M., Reich, A. (2018). Improvement of endovascular stroke treatment: A 24-hour neuroradiological on-site service is not enough. BioMed Research International, 2018, 1-8. doi: 10.1155/2018/9548743.

Nogueira, R.G., Jadhav, A.P., Haussen, D.C., Bonafe, A. Budzik, R. F., Bhuva, P.,...Jovin, T. G. (2018) Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. The New England Journal of Medicine, 378, 11-21. doi: 10.1056/NEJMoa1706442.

Palmer, R. (2015) Innovations in aphasia treatment after stroke: Technology to the rescue. British Journal of Neuroscience Nursing, 38-42. doi: 10.12968/bjnn.2015.11.Sup2.38.

Park, S. W., Yi, S. H., Lee, J. A., Hwang, P. W., Yoo, H. C., & Kang, K. S. (2014). Acupuncture for the treatment of spasticity after stroke: a meta-analysis of randomized controlled trials. Journal of alternative and complementary medicine, 20(9), 672-82. doi: 10.1089/acm.2014.0097.

Powers, W.J., Rabinstein, A.A., Ackerson, T., Adeoye, O.M., Bambakidis, N.C., Becker, K.,... Tirschwell, D.L. (2018). Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 49, e46–e99. doi: 10.1161/STR.0000000000000158.

Riegel, B., Moser, D.K., Buck, H.G., Dickson, V.V., Dunbar, S.B., Lee, C.S.,... Webber, D.E. (2017). Self-care for the prevention and management of cardiovascular disease and stroke: a scientific statement for healthcare professionals from the American Heart Association. J Am Heart Assoc, 6, e006997. doi: 10.1161/JAHA.117.006997.

Saver, J.L., Goyal, M., Bonafe, A., Diener, H.C., Levy, E.I., Pereira, V.M.,.... Jahan, R. (2015). Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. The New England Journal of Medicine, 372, 2285–2295. doi: 10.1056/NEJMoa1415061.


Saver, J.L., Goyal, M., van der Lugt, A., Menon, B. J., Majoie, C. B. L. M., Dippel, D. W.,... Hill, M. D. (2016). Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: A meta-analysis. JAMA. 316(12), 1279-89. doi: 10.1001/jama.2016.13647.

Scheinfeld, M.H., Erdfarb, A.J., Krieger, D.A., Bhupali, D. & Zampolin, R. L. (2016). A radiologist’s guide to the clinical scales used in the 2015 Endovascular Stroke Trials and the Revised American Heart Association/American Stroke Association Guidelines for Endovascular Stroke Treatment. Emerg Radiol 23, 497-501. doi: 10.1007/s10140-016-1420-3.

Schröder, J. & Thomalla, G. (2017). A critical review of Alberta Stroke Program Early CT Score for evaluation of acute stroke imaging. Frontiers in Neurology, 7, 245. doi: 10.3389/fneur.2016.00245.

Spiotta, A.M., Chaudry, M.I., Hui, F.K., Turner, R. D., Kellogg, R. T. & Turk, A. S. (2015). Evolution of thrombectomy approaches and devices for acute stroke: a technical review. J NeuroIntervent Surg, 7, 2–7. doi: 10.1136/neurintsurg-2013-011022.

The Joint Commission (JCAHO). (2018a). Facts about Joint Commission stroke certification. Retrieved December 21, 2018, from

The Joint Commission (JCAHO). (2018b). Specifications Manual for Joint Commission National Quality Measures. Retrieved December 18, 2018, from

Tomioka, K., Matsumoto, S., Ikeda, K., Uema, T., Sameshima, J. I., Sakashita, Y., Kaji, T., … Shimodozono, M. (2017). Short-term effects of physiotherapy combining repetitive facilitation exercises and orthotic treatment in chronic post-stroke patients. Journal of Physical Therapy Science, 29(2), 212-215. doi: 10.1589/jpts.29.212.

U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). (2018, August). Stroke Education Materials for Health Professionals. Retrieved December 19, 2018, from

U.S. Department of Health and Human Services, National Heart, Lung, and Blood Institute (NHLBI). (n.d.). Stroke. Retrieved December 20, 2018, from

U.S. Department of Health and Human Services, National Institute of Neurological Disorders and Stroke (NINDS). (2018). Cerebral Aneurysms Fact Sheet (NIH Publication No. 18-NS-5506). Retrieved January 8, 2019 from

University of Miami Health System (n.d.) Stroke. Retrieved on January 11, 2019 from

Wändell, P., Carlsson, A. C., Holzmann, M., Ärnlöv, J., Johansson, S. E., Sundquist, J., & Sundquist, K. (2016). Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation-a cohort study in primary care. European Journal of Clinical Pharmacology, 73(2), 215-221. doi: 10.1007/s00228-016-2152-8.

Winstein, C.J., Stein J., Arena, R., Bates, B., Cherney, L.R., Cramer, S.C.,... Zorowitz, R.D. (2016). Guidelines for adult stroke rehabilitation and recovery: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 47, e98–e169. doi: 10.1161/STR.0000000000000098.

World Health Organization. (2017, May). Cardiovascular diseases (CVDs) Fact Sheet. Retrieved December 18, 2018, from

Yaghi, S., Willey, J.Z., Cucchiara, B., Goldstein, J.N., Gonzales, N.R., Khatri, P.,... Schwamm, L.H. (2017) Treatment and outcome of hemorrhagic transformation after intravenous